Business Model Breakdown
How LifeVantage Corp Makes Money
LFVN
Market Cap
$99M
Annual Revenue
$44M
Profit Margin
2.9%
Employees
232
The Short Version
LifeVantage Corp. develops, markets, and sells nutrigenomic dietary supplements, skin and hair care products, and energy drinks. The company primarily uses a direct-selling network of independent distributors to reach customers globally. Distributors earn commissions on product sales and by recruiting new distributors, while customers purchase products directly from distributors or the company's e-commerce platform. The business model relies heavily on distributor engagement, product efficacy, and direct-to-consumer digital outreach to drive sales in the health and wellness market.
Where the Revenue Comes From
Nutrigenomic dietary supplements sales (~70-80% of revenue, estimated based on primary focus)
Skin and hair care products sales (~10-20% of revenue, estimated)
Energy drink sales (~5-10% of revenue, estimated)
Who buys: Independent distributors who purchase products for resale and personal use, and end-consumers purchasing directly from distributors or online.
Why It Works (Competitive Advantages)
- ✔Proprietary nutrigenomic formulations (IP/Intangible Assets)
- ✔Established direct-selling distribution network (albeit facing challenges)
- ✔Cash on hand with no debt (balance sheet strength)
Economic Moat: None (Brand Power (limited, primarily among distributors), Intangible Assets/IP (proprietary formulas, but easily mimicked or improved upon by larger players))
What Our Analysis Says
DVR Score as of June 2, 2026
LifeVantage Corp (LFVN) has seen a significant deterioration in its near-term prospects, moving further away from its stated 10x growth potential. The Q3 FY2026 earnings report on May 6, 2026, revealed a sharp 25.2% year-over-year revenue decline and a 57.7% drop in EPS, missing analyst estimates on both counts. Management's revised full-year guidance to the 'lower end' further dampens expectations. While the company maintains a healthy balance sheet with no debt and positive operating cash flow, and even increased its dividend, the core issue of declining sales, particularly from its MindBody GLP-1 System, signals that the digital-first pivot has not yet stemmed the bleeding, let alone initiated growth. The path to significant market share and substantial growth is now considerably steeper, making the 10x potential highly speculative and dependent on an improbable reversal of current trends.